Financials
Financial year 2025
JOHNSON & JOHNSON MEDICAL from Machelen (Brab.), company number BE0425967580, closed financial year 2025 with a result of € 10.2 million after tax. For that financial year JOHNSON & JOHNSON MEDICAL recorded revenue of € 330 million and equity of € 80.2 million. Compared with financial year 2024, the result moved from € 9.4 million to € 10.2 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 80.2 million
▲ 15% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 10.2 million
▲ 9% vs 2024
Profit after tax over the fiscal year.
€ 2.1 million
▲ 22% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 71.6 million.
People and assets in 2025
267.5
▲ 8.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 58.2 million
▲ 18% vs 2024
€ 217,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 9,024
▼ 18% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 0
Loans from banks and other lenders, long and short.
€ 110 million
▲ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 145 days on average.
€ 14.6 million
▲ 27% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 341,828,014 | € 346,678,073 | € 329,692,902 | € 330,019,973 | |
| Profit after taxes | € 6,376,564 | € 7,713,047 | € 9,380,148 | € 10,220,048 | ▲ 9% |
| Equity | € 52,855,048 | € 60,568,096 | € 69,948,244 | € 80,168,292 | ▲ 15% |
| Total debts | € 71,528,180 | € 122,426,255 | € 121,440,792 | € 136,504,853 | ▲ 12% |
| Cash | € 1,768,462 | € 2,067,503 | € 1,688,391 | € 2,053,084 | ▲ 22% |
| Retained profit | € 44,322,322 | € 52,035,369 | € 61,415,518 | € 71,635,566 | ▲ 17% |
| Dividend | € 35,000,000 | € 0 | € 0 | € 0 | |
| Bank debt | € 6,532 | € 1,820 | € 0 | € 0 | |
| Balance sheet total | € 132,031,949 | € 190,643,071 | € 199,068,206 | € 225,600,003 | ▲ 13% |
| Employees (FTE) | 261.8 | 264.6 | 259.1 | 267.5 | ▲ 8.4 |
Key figures of JOHNSON & JOHNSON MEDICAL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to JOHNSON & JOHNSON MEDICAL?
What happened at JOHNSON & JOHNSON MEDICAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Bram Van Elsen stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 10.2 million (▲ 9% vs 2024). Source: NBB ↗
- Katrien Lindemans stepped down as director. NBB
- Bert Van Opdenbosch stepped down as director. NBB
- Bram Van Elsen became a director. NBB
- Fabrice Degenève stepped down as director. NBB
- Fabrice Degenève became a director. NBB
- Katrien Lindemans became a director. NBB
In short
From € 6.4 million profit in 2022 to € 10.2 million profit in 2025.
Paid € 13.2 million in corporate taxes since 2022.
Best year ever: 2025, with € 10.2 million profit.
Paid out € 35 million in dividends to the owners in total.
Management
The stake of Janssen Pharmaceutica comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
JOHNSON & JOHNSON MEDICALThe shares are held by Janssen Pharmaceutica (0%). It owns 100% of JJSV Belgium itself.
Directors
According to the 2025 annual accounts
Bram Van Elsen
Managing director
since 2026 · until 2031
Katrien Lindemans
Managing director
since 2021 · until 2026
Fabrice Degenève
Managing director
since 2024 · until 2026
Bert Van Opdenbosch
Managing director
since 2021 · until 2026
Shareholders
Participations
100%
Establishments
Establishment units
Physical locations of this company
Leonardo da Vincilaan 15
1831 Machelen (Brab.)
Antwerpseweg 15-17
2340 Beerse
Active since 1 January 2013
Turnhoutseweg 30
2340 Beerse
Active since 1 August 2013
Antwerpseweg 19-21
2340 Beerse
Active since 31 March 2014
Rue du Luxembourg(CO) 5
6180 Courcelles
Active since 1 November 2014
de Meeûssquare 23
1000 Brussel
Active since 1 June 2015
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →OMRIX BIOPHARMACEUTICALS
€ 107 million revenue · 2025
BELGIUM - LUXEMBOURG ORACLE USER GROUP
JJSV Belgium same network
€ 7.6 million revenue · 2024
GMED HEALTHCARE
€ 3.6 billion revenue · 2025
DePuy Synthes (Belgium)
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0425.967.580
- VAT number
- BE 0425.967.580
- Registered office
- Leonardo da Vincilaan 15, 1831 Machelen (Brab.)
- Names & denominations
- JOHNSON & JOHNSON MEDICAL · J&J Medical, Ethicon, CSS, DePuy Synthes, J&J Vision, Biosense Webster
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 7 June 1984
- Peppol
- Active · Active since 18 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels